What is the 13F Pro Quality Score for ADPT?

13F Pro ranks Adaptive Biotechnologies Corp (ADPT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ADPT's current score at https://13fpro.ai/research/ADPT (free sign-up required for the full ranking).

Which hedge funds own the most ADPT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ADPT include VIKING GLOBAL INVESTORS, BlackRock,, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ADPT as soon as new 13F filings post.

Where does 13F Pro source ADPT data?

All Adaptive Biotechnologies Corp fundamentals and ownership data come directly from SEC EDGAR. Adaptive Biotechnologies Corp files with the SEC under CIK 1478320. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ADPT in?

Adaptive Biotechnologies Corp (ADPT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ADPT research updated on 13F Pro?

ADPT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Adaptive Biotechnologies Corp(ADPT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1478320 ADPT stock profile & AI dashboard →

13F Pro Quality Score

35.2/100

Rank #2,156 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

86.8/100

Profitability

17.0/100

Balance Sheet

15.1/100

Earnings Quality

30.0/100

Free Cash Flow

13.4/100

Institutional Flow

79.0/100

Revenue Scale

28.3/100

Dilution Risk

10.0/100

ADPT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Adaptive Biotechnologies Corp (ADPT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ADPT at 35.2/100 on a 32-signal composite quality model, placing it at rank #2,156 of 2,879 stocks — the bottom half of the AI-ranked universe. ADPT scores in the top quartile across revenue growth (86.8), institutional flow (79.0). Areas of concern include free cash flow (13.4) and balance sheet strength (15.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Adaptive Biotechnologies Corp reports quarterly revenue of $70.9M, net income of $-20.0M, free cash flow of $-10.3M. Top institutional holders of ADPT by reported 13-F value include VIKING GLOBAL INVESTORS, BlackRock,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ADPT trades on the Nasdaq exchange and files with the SEC under CIK 1478320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADPT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Adaptive Biotechnologies Corp directly from SEC EDGAR. Adaptive Biotechnologies Corp's 13F Pro composite quality score has ranged between 8 and 74 since 2021, currently 35.2 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Adaptive Biotechnologies Corp

Quirks, history, and lore behind ADPT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · listed on Nasdaq · headquartered in Seattle, Washington · operates at the intersection of genomics and immunology.
2
The Numbers
Annual revenue in the low hundreds of millions — this is still a clinical-stage-adjacent biotech, meaning it spends more than it earns while betting big on the future of immune medicine.
3
The History
Founded around 2009, it grew out of ambitions to decode the human immune system at scale — a goal that once seemed like science fiction and still impresses immunologists today.
4
The Secret
Its core technology maps the T-cell and B-cell receptors of millions of patients, essentially reading the immune system's memory like a biological hard drive.
5
The Lore
It struck a high-profile collaboration with Microsoft to use machine learning on its massive immune-sequencing database — pairing biology with cloud computing in a genuinely novel way.
6
The Giveaway
Its flagship platform, immunoSEQ, sequences the immune repertoire, and its clonoSEQ test is FDA-authorized to detect cancer cells hiding in blood cancers down to one-in-a-million — this is Adaptive Biotechnologies territory.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$70.9M

Net Income

Q1 2026

$-20.0M

Free Cash Flow

Q1 2026

$-10.3M

D/E Ratio

Q1 2026

0.60

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+54.8% YoY

$277.0MFY 2025

FY21 $154.3MFY22 $185.3MFY24 $179.0MFY25 $277.0M

Net Income

+62.7% YoY

$-59.5MFY 2025

FY21 $-207.3MFY22 $-200.2MFY24 $-159.5MFY25 $-59.5M

Operating Income

+64.9% YoY

$-57.1MFY 2025

FY21 $-209.0MFY22 $-200.2MFY24 $-162.5MFY25 $-57.1M

EPS (Diluted)

+63.9% YoY

$-0.39FY 2025

FY21 $-1.48FY22 $-1.40FY24 $-1.08FY25 $-0.39

Total Assets

-4.9% YoY

$512.7MFY 2025

FY21 $923.3MFY22 $856.6MFY24 $539.4MFY25 $512.7M

Total Debt

-1.6% YoY

$131.2MFY 2025

FY21 —FY22 $125.4MFY24 $133.3MFY25 $131.2M

Op. Cash Flow

+51.7% YoY

$-46.0MFY 2025

FY21 $-192.7MFY22 $-183.9MFY24 $-95.2MFY25 $-46.0M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$277.0M +54.8%	$179.0M -3.4%	$185.3M +20.1%	$154.3M +56.9%	$98.4M +15.6%	$85.1M
Net Income	$-59.5M +62.7%	$-159.5M +20.3%	$-200.2M +3.4%	$-207.3M -41.8%	$-146.2M -113.1%	$-68.6M
Operating Income	$-57.1M +64.9%	$-162.5M +18.8%	$-200.2M +4.2%	$-209.0M -36.7%	$-152.8M -94.9%	$-78.4M
EPS (Diluted)	$-0.39 +63.9%	$-1.08 +22.9%	$-1.40 +5.4%	$-1.48 -33.3%	$-1.11	—
Total Assets	$512.7M -4.9%	$539.4M -37.0%	$856.6M -7.2%	$923.3M -17.3%	$1.12B +22.4%	$912.3M
Total Debt	$131.2M -1.6%	$133.3M +6.3%	$125.4M	—	—	—
Operating Cash Flow	$-46.0M +51.7%	$-95.2M +48.2%	$-183.9M +4.6%	$-192.7M -28.8%	$-149.7M -172.9%	$205.4M

AI Insight: ADPT Financial Trends

Profitability inflection in Q3 2025 reversed in Q4–Q1 2026; revenue momentum stalled despite earlier acceleration.

• Revenue grew 65% from Q2 2025 ($59M) to Q3 2025 ($94M), then declined 23% to Q4 2025 ($72M) and further to $71M in Q1 2026.

• Q3 2025 achieved $10M operating income and $10M net income—only profitable quarter—but reverted to $-13M and $-14M operating/net losses in Q4 2025.

• Debt held stable at $131M–$134M across eight quarters while equity declined 10% from $242M (Q2 2024) to $216M (Q1 2026).

⚠ Q3 2025 profitability appears unsustainable; losses resumed immediately. Investigate whether Q3 spike was one-time revenue or demand normalization.

⚠ Operating cash flow remains negative in 6 of 8 quarters; even profitable Q3 2025 generated only $-7M OCF, signaling cash burn continues.

AI Insight: ADPT Ratio Trends

ADPT briefly turned profitable in Q3 2025 but has since deteriorated sharply, with Q1 2026 margins collapsing back to -27.1% operating loss.

• Operating margin swung from -42.5% in Q2 2025 to +10.9% in Q3 2025, then reversed to -27.1% in Q1 2026—indicating unsustainable profitability.

• ROIC improved from -50.6% in Q2 2024 to -22.1% in Q1 2026, yet remains deeply negative and volatile across all recent quarters.

• Debt-to-equity ratio stable around 0.60–0.74 range; Q1 2026 leverage at 0.60, consistent with TTM leverage, suggesting no balance-sheet deterioration.

⚠ Q3 2025 profitability was an anomaly, not a trend—Q4 2025 and Q1 2026 both reverted to double-digit operating losses. Root cause unknown.

⚠ All return metrics (ROE, ROA, ROIC) have turned deeply negative in Q1 2026; company destroying shareholder value at an accelerating pace.

Get alerted when ADPT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Adaptive Biotechnologies Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ADPT

VIKING GLOBAL INVESTORS LP
$416.3M29,993,708 sh
BlackRock, Inc.
$184.6M13,303,025 sh
VANGUARD CAPITAL MANAGEMENT LLC
$84.6M6,094,144 sh
WESTFIELD CAPITAL MANAGEMENT CO LP
$75.5M5,436,718 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$62.3M4,491,474 sh
Invesco Ltd.
$61.8M4,450,066 sh
WELLINGTON MANAGEMENT GROUP LLP
$53.5M3,857,422 sh
GEODE CAPITAL MANAGEMENT, LLC
$50.5M3,636,054 sh
GOLDMAN SACHS GROUP INC
$45.0M3,242,077 sh
STATE STREET CORP
$44.8M3,227,245 sh

Fund	Value	Shares
VIKING GLOBAL INVESTORS LP	$416.3M	29,993,708
BlackRock, Inc.	$184.6M	13,303,025
VANGUARD CAPITAL MANAGEMENT LLC	$84.6M	6,094,144
WESTFIELD CAPITAL MANAGEMENT CO LP	$75.5M	5,436,718
VANGUARD PORTFOLIO MANAGEMENT LLC	$62.3M	4,491,474
Invesco Ltd.	$61.8M	4,450,066
WELLINGTON MANAGEMENT GROUP LLP	$53.5M	3,857,422
GEODE CAPITAL MANAGEMENT, LLC	$50.5M	3,636,054
GOLDMAN SACHS GROUP INC	$45.0M	3,242,077
STATE STREET CORP	$44.8M	3,227,245

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ADPT on your watchlist

Track score changes the day Adaptive Biotechnologies Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ADPT a good stock to buy?

13F Pro's AI-powered analysis of Adaptive Biotechnologies Corp (ADPT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ADPT are available on the ADPT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ADPT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ADPT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Adaptive Biotechnologies Corp's investment landscape.